AbbVie Inc. vs Eli Lilly and Company: Strategic Comparison

This in-depth comparison examines AbbVie Inc. and Eli Lilly and Company across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching AbbVie Inc. on its own, evaluating Eli Lilly and Company, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between AbbVie Inc. and Eli Lilly and Company is widest.

On the headline numbers, AbbVie Inc. reports annual revenue of $61.2B against $65.2B for Eli Lilly and Company, while their respective market capitalizations stand at $465.8B and $1.06T. AbbVie Inc. is headquartered in United States and Eli Lilly and Company operates from United States, and those different home markets shape how each company competes.

AbbVie Inc.: AbbVie became an independent public biopharmaceutical company in January 2013 after Abbott Laboratories separated its research-based pharmaceutical business. Humira initially dominated its portfolio. AbbVie has since added Pharmacyclics, Allergan, ImmunoGen, and Cerevel and now reports major portfolios in immunology, neuroscience, oncology, and aesthetics.

Eli Lilly and Company: Eli Lilly is a 150-year-old Indianapolis pharmaceutical company that has become the world's largest drugmaker by market value. For most of its history it was best known for insulin and Prozac. Since 2022, tirzepatide, a dual GIP/GLP-1 agonist sold as Mounjaro for type 2 diabetes and Zepbound for obesity, has transformed its scale, taking revenue from $28.5 billion in 2022 to $65.2 billion in 2025 and a guided $85-87 billion in 2026.

AbbVie Inc. and Eli Lilly and Company pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between AbbVie Inc. and Eli Lilly and Company.

AbbVie Inc. business model: AbbVie earns revenue from global sales of prescription medicines and Allergan Aesthetics products. Its FY2025 portfolios were led by immunology at $30.406 billion, neuroscience at $10.767 billion, oncology at $6.655 billion, and aesthetics at $4.860 billion. The company funds internal research and supplements its pipeline through licensing and acquisitions.

Eli Lilly and Company business model: Lilly makes money by discovering, developing, manufacturing and selling patent-protected prescription medicines. Revenue comes mainly from product sales to wholesalers, pharmacies and health systems, with net prices set through negotiations with insurers, pharmacy benefit managers and governments; collaboration and royalty income adds a smaller share. Cardiometabolic medicines dominate: Mounjaro ($22.97 billion) and Zepbound ($13.54 billion) together produced about 56% of 2025 revenue. Lilly also sells directly to self-pay patients through LillyDirect, including Zepbound vials and Foundayo tablets, which reduces reliance on traditional pharmacy benefit channels for obesity care.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of AbbVie Inc. stack up against those of Eli Lilly and Company.

AbbVie Inc. competitive advantage: AbbVie's scale rests on its immunology portfolio, specialist commercial infrastructure, approved products across several therapeutic areas, and acquired oncology, neuroscience, and aesthetics assets. Those strengths are offset by patent-expiration, clinical-development, safety, reimbursement, and pricing risks described in its Form 10-K.

Eli Lilly and Company competitive advantage: Lilly's advantage combines a century of diabetes and peptide-hormone expertise with manufacturing scale few rivals can match. Tirzepatide's dual GIP/GLP-1 mechanism produced greater weight loss than semaglutide in the head-to-head SURMOUNT-5 trial, and Foundayo gives Lilly a small-molecule GLP-1 pill that can be taken without food or water restrictions and is easier to mass-produce than peptides. Heavy investment in U.S. and European plants lets Lilly supply volume growth that competitors struggle to match.

Future prospects matter as much as current results. The growth strategies below explain how AbbVie Inc. and Eli Lilly and Company each plan to expand from here.

AbbVie Inc. growth strategy: AbbVie is expanding approved uses and commercial reach for Skyrizi and Rinvoq while investing in oncology and neuroscience. ImmunoGen added Elahere and antibody-drug conjugate programs, Cerevel added clinical-stage neuroscience programs, and Allergan added Botox, Vraylar, migraine products, eye care, and aesthetics.

Eli Lilly and Company growth strategy: Lilly's growth strategy has three parts: expand incretin supply and indications, add oral and next-generation obesity medicines, and diversify through oncology, immunology, neuroscience and genetic medicine. Foundayo (orforglipron) was approved by the FDA on April 1, 2026 and launched through LillyDirect, telehealth and U.S. retail pharmacies. Retatrutide, a GIP/GLP-1/glucagon triple agonist, is in Phase 3. Lilly continues to build U.S. and European manufacturing capacity and uses acquisitions to add pipeline assets.

A closer look at the financial trajectory of AbbVie Inc. and Eli Lilly and Company rounds out the comparison.

AbbVie Inc.: AbbVie reported $61.160 billion of FY2025 net revenue and $4.226 billion of net income. Skyrizi and Rinvoq generated $25.866 billion combined, while Humira declined to $4.540 billion after U.S. biosimilar entry. The 2020 Allergan acquisition added neuroscience and aesthetics revenue, and the 2024 ImmunoGen and Cerevel acquisitions added oncology and neuroscience assets.

Eli Lilly and Company: Revenue rose from $28.5 billion in 2022 to $45.0 billion in 2024 and $65.2 billion in 2025, while net income nearly doubled to $20.6 billion. Growth accelerated again in 2026: second-quarter revenue rose 48% to $23.0 billion, with Mounjaro at $9.94 billion (up 91%) and Zepbound at $4.93 billion. Lilly raised 2026 revenue guidance to $85-87 billion and non-GAAP EPS guidance to $35.50-36.50. Capital expenditures reached $7.8 billion in 2025 as Lilly expanded production capacity.